Cell Counting Devices Market size was valued at US$ 7,947.61 million in 2022 and is estimated to reach US$14,725.39 million by 2029, growing at a CAGR of 7.84% during the forecast period (2022-2029).
The cell counting devices are utilized for the quantification of the number of cells present in the sample. These devices are ideal for blood sample analysis which includes differential cell counters, counting chambers and hemocytometers. Cell counting devices provide dead cell or viable cell count as well as analysis for cell culture or cellular assays.
Cell Counting Devices Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Cell Counting Devices Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Cell Counting Devices Market in the United States and Canada produces the utmost share. Whereas the European Cell Counting Devices Market is projected to continue its presence globally during the period of 2022- 2029.
Cell Counting Devices Market
By Product Type, By Application, By End-User, and By Region
Report Insights Covered
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region
Largest Market Share
To Get a Free Sample Click here
The major factors driving the global cell counting devices market are an increase in the prevalence of infectious blood infections across the globe and awareness among the population regarding infectious diseases. An increase in novel technological advancements and product launches contributes to the growth of the cell-counting devices market.
The increasing demand for devices and novel technological advancements are expected to drive the market’s growth.
The cell counting devices market is driven by rising technological advancements, an increase in the geriatric and disabled population, and the rising number of novel product launches. An increase in infectious blood disease cases is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop advanced products such as instruments, consumables, and software.
Cell counting devices are used in various applications such as blood count, stem cell research, and immunology research. The market for these applications is increasing worldwide due to the increasing number of infectious disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market’s growth.
Various novel product launches and research studies contribute to the market’s growth. For instance, in Sep 2020, Paul Marienfeld GmbH & Co. KG announced the availability of its novel Cellcounter, an electronic blood counter that is voltage-independent and developed for counting blood cells. It provides users with work flexibility as it can be operated via a plug-in power supply unit from the mains as a mobile device.
The high cost associated with these devices and the stringent regulations is expected to hamper the market’s growth.
However, stringent government regulations for developing and manufacturing cell count device products, including blood culture test products, could hinder market growth. Products undergo multiple trials for approval which increases the cost of development.
COVID-19 Impact Analysis
The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The cell counting devices market has experienced huge profits due to COVID, as various research and clinical trials started in full swing due to the increasing cases of COVID. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Feb 2022, Agilent Technologies Inc. highlighted its innovative laboratory automation solutions at SLAS2022 International Conference and Exhibition in Boston. This modular solution mentions the wide array of mass spectrometry and cell analysis in regulated and development environments.
The instruments segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The instruments segment is the largest market shareholder due to its advantages, increasing technological advancements and novel product launches.
The market for instruments is further segmented into the spectrophotometer, flow cytometers, haematology analysers, cell counters and others. A spectrophotometer evaluates emitted photons amount to determine the absorbance or transmittance of the intensity of light.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in Mar 2022, Tip Biosystems, an agile spectrophotometry provider, announced Photopette Aqua, its most versatile, the latest member of Photopette spectrophotometers. Photopette Aqua is a portable handheld device that can evaluate several aqueous parameters. It is a Merck and Tip Biosystem collaboration product that was developed to use Merck’s Spectroquant reagent test kits for several parameters.
North America holds the largest market share in the global cell counting devices market.
North America dominates the global cell counting devices market, primarily due to its large population combined with excellent medical infrastructure and the rising number of people suffering from chronic diseases. According to National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO, the number of new cases is expected to rise by around 70% by 2030.
Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of applications of cell counting devices in total blood count and research applications, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the cell counting devices market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Apr 2020, Bio-Rad Laboratories, a clinical diagnostic and life science research company, announced its acquisition of Celsee Inc., a consumables and instruments provider for single cell detection and analysis.
The cell counting devices market is highly competitive with local and global companies’ presence. Thermo Fisher Scientific, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Becton, Dickinson and Company, Merck KGaA, Corning Inc., Chemometec A/S, Tip Biosystems, Paul Marienfield GmbH & Co. KG, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Aug 2022, Bio-Rad Laboratories, a clinical diagnostic and life science research company, announced its acquisition agreement with Curiosity Diagnostics from Scope Fluidics, an innovative technology solutions provider for healthcare and medical diagnostics.
Thermo Fisher Scientific.
Overview: Thermo Fisher Scientific is a healthcare distributor company that serves science. They manufacture and market reagents, scientific instruments & equipment, consumables and software services. It was established in 1956 and is based in Waltham, Massachusetts, United States.
VersaTREK REDOX EZ Draw Media: It is a culture media that is simple, convenient, and safe to perform phlebotomy that does not require expensive blood adapters. Its FDA cleared that accommodate around 5mL of blood. EZ draw media can be used for automatic or manual monitoring of blood samples generally accessible in 40mL broth for aerobic REDOX-1 and anaerobic REDOX-2. REDOX media is highly-enriched and supports a variety of organisms that enhance the VersaTREK system.
Key Development: In Jun 2021, Thermo Fisher Scientific Inc. launched its Invitrogen Attune CytPix, a flow cytometer with imaging-enhanced technology combining a high-speed camera with acoustic focusing cytometry. It provides users with high-performance fluorescent flow cytometry data along with high-resolution images for a better understanding of the morphology of cells.
The global cell counting devices market report would provide access to approx. 45+market data table, 40+figures and 200 (approximate) pages.
What is the Projected CAGR value of the Cell Counting Devices Market?
Cell Counting Devices Market is expected to grow at a CAGR of 8.1% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Cell Counting Devices Market during 2022-2029
Which is the fastest growing region in the Cell Counting Devices Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
Get your free sample proposal with a single click!